| # | Drug | Count |
|---|---|---|
| 0 | HUMAN IMMUNOGLOBULIN G | 33 |
| 1 | PREDNISONE | 19 |
| 2 | LEVOTHYROXINE SODIUM | 18 |
| 3 | ACETAMINOPHEN | 17 |
| 4 | IBRUTINIB | 17 |
| 5 | DIPHENHYDRAMINE HYDROCHLORIDE | 16 |
| 6 | LENALIDOMIDE | 16 |
| 7 | RITUXIMAB | 15 |
| 8 | ACETAMINOPHEN 500MG | 14 |
| 9 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 14 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ELRANATAMAB-BCMM | 2 | 0.0017 |
| 1 | HUMAN IMMUNOGLOBULIN G | 33 | 0.0016 |
| 2 | IMMUNE GLOBULIN INFUSION (HUMAN) | 13 | 0.0015 |
| 3 | FROVATRIPTAN SUCCINATE | 1 | 0.0013 |
| 4 | IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN) | 4 | 0.0009 |
| 5 | METHENAMINE HIPPURATE | 1 | 0.0008 |
| 6 | IMMUNE GLOBULIN INFUSION (HUMAN), 10% WITH RECOMBINANT HUMAN HYALURONIDASE | 3 | 0.0007 |
| 7 | LANADELUMAB-FLYO | 2 | 0.0006 |
| 8 | CAPLACIZUMAB | 1 | 0.0006 |
| 9 | EFGARTIGIMOD ALFA | 2 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 46 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 33 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 30 |
| 3 | Human Immunoglobulin G [EPC] | 27 |
| 4 | Kinase Inhibitor [EPC] | 22 |
| 5 | Thalidomide Analog [EPC] | 22 |
| 6 | Proton Pump Inhibitor [EPC] | 16 |
| 7 | Osmotic Laxative [EPC] | 13 |
| 8 | Benzodiazepine [EPC] | 12 |
| 9 | Tumor Necrosis Factor Blocker [EPC] | 12 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Human Immunoglobulin G [EPC] | 27 | 0.0013 |
| 1 | Neonatal Fc Receptor Blocker [EPC] | 2 | 0.0005 |
| 2 | CD19-directed Chimeric Antigen Receptor [EPC] | 3 | 0.0003 |
| 3 | Leukotriene Receptor Antagonist [EPC] | 6 | 0.0002 |
| 4 | Tissue-nonspecific Alkaline Phosphatase [EPC] | 2 | 0.0002 |
| 5 | Antimetabolite Immunosuppressant [EPC] | 3 | 0.0001 |
| 6 | Dopamine-2 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 7 | Glinide [EPC] | 1 | 0.0001 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 33 | 0.0001 |
| 9 | CD52-directed Cytolytic Antibody [EPC] | 2 | 0.0001 |